4426-03-3

Basic information

• Product Name: CYCLOBUTYLACETONITRILE
• Synonyms: CYCLOBUTYLACETONITRILE;cyclobutylacetonitrile(SALTDATA: FREE);2-cyclobutylethanenitrile
• CAS NO: 4426-03-3
• Molecular Formula: C₆H₉N
• Molecular Weight: 95.14236
• Mol File: 4426-03-3.mol

Chemical Properties

• Boiling Point: 181.2°C at 760 mmHg
• Flash Point: 70.1°C
• Appearance: /
• Density: 0.933g/cm³
• Vapor Pressure: 0.86mmHg at 25°C
• Refractive Index: 1.455
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CYCLOBUTYLACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOBUTYLACETONITRILE(4426-03-3)
• EPA Substance Registry System: CYCLOBUTYLACETONITRILE(4426-03-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 4426-03-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
CYCLOBUTYLACETONITRILE is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, leveraging its versatile chemical properties to create a wide range of products.
Used in Organic Synthesis:
It is utilized as a solvent and intermediate in organic synthesis, contributing to the formation of complex organic compounds.
Used in Perfume and Flavoring Agent Production:
CYCLOBUTYLACETONITRILE is used as a component in the production of perfumes and flavoring agents, capitalizing on its aromatic properties to enhance the scent and taste of various products.

InChI:InChI=1/C6H9N/c7-5-4-6-2-1-3-6/h6H,1-4H2

Upstream product

• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 143-33-9 sodium cyanide 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 151-50-8 potassium cyanide 
• 1191-95-3 cyclobutanone 
• 105-34-0 methyl 2-cyanoacetate 
• 773837-37-9 sodium cyanide 
• 13295-53-9 cyclobutylmethyl 4-methylbenzenesulfonate 
• 5006-22-4 Cyclobutanecarbonyl chloride 
• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 4415-82-1 cyclobutanemethanol 
• 3721-95-7 Cyclobutanecarboxylic acid 

Downstream Products

• 885280-12-6 ethyl 4-cyclobutyl-3-oxobutanoate 
• 1433545-62-0 4-cyclobutyl-1-ethoxy-1,3-dioxobutan-2-yl 4-methoxybenzoate 
• 1433545-74-4 (2E)-3-amino-4-cyclobutyl-1-ethoxy-1-oxobut-2-en-2-yl 4-methoxybenzoate 
• 1433545-85-7 3-[(tert-butoxycarbonyl)amino]-4-cyclobutyl-1-ethoxy-1-oxobut-2-yl 4-methoxybenzoate 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 394730-60-0 boceprevir 
• 91639-80-4 cyclobutyl-acetic acid anilide 
• 909717-49-3 (S)-2-Cyclobutyl-pent-4-enoic acid 3,5-bis-trifluoromethyl-benzylamide 
• 909717-47-1 (S)-4-Benzyl-3-((S)-2-cyclobutyl-pent-4-enoyl)-oxazolidin-2-one 
• 144164-36-3 (S)-4-Benzyl-3-(2-cyclobutyl-acetyl)-oxazolidin-2-one 

Relevant articles and documents

Rate constants and Arrhenius functions for ring opening of a cyclobutylcarbinyl radical clock and for hydrogen atom transfer from the Et 3B-MeOH complex

(Chemical Equation Presented) Kinetics of ring opening of the 1-cyclobutyldodecyl radical (1) were studied, and an Arrhenius function over the temperature range -20 to 47°C was determined. The radical clock reaction has kinetics described by log k = 13.2-13.5/2.313RT (in kcal/mol), and k = 1.5 × 103 s-1 at 20°C. Previous kinetic studies of hydrogen atom transfer trapping of radical 1 by the triethylborane-methanol complex at variable temperatures (J. Org. Chem. 2007, 72, 5098) were analyzed with the newly obtained kinetic data.

TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS

Compounds having activity as cancer agents are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salts, stereoisomers, tautomers, thereof, wherein R1, R2, R3 and L are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating a CDK7-dependent disease (e.g., cancer).

Formal reductive addition of acetonitrile to aldehydes and ketones

An efficient and highly productive rhodium-catalyzed method for the synthesis of nitriles employing aldehydes or ketones, methyl cyanoacetate, water and carbon monoxide as starting materials has been developed. Simple rhodium chloride without any ligands can be used. The fine tuning of the substrate can lead to the activity higher than 5000 TON.

PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF

The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or lnterleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

Piperazine derivatives and their use as therapeutic agents

Compounds for treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the compounds are of formula (I): where x y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

THIAZOLES AS MODULATORS OF RORyt

The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and (A) are defined in the specification. The invention also comprises a co

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 3-AMINO-4-CYCLOBUTYL-2-HYDROXYBUTANAMIDE AND SALTS THEREOF

The present invention relates to synthetic processes useful in the preparation of a compound of Formula (I), and salts thereof. Compounds of Formula (I) and salts thereof have application in the preparation of inhibitors of the hepatitis C virus, such as (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

SYNTHESIS OF TELAPREVIR AND BOCEPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF INCLUDING ?-AMINO ACIDS PREPARED VIA MUKAIYAMA ALDOL ADDITION

The invention relates to synthetic routes for preparing telaprevir and boceprevir, and its intermediates as well as peptides other than telaprevir. The synthetic routes are based on a Mukaiyama aldol addition reaction of a silyl enol ether or an enolate with an imine. The invention also refers to novel intermediates for preparing telaprevir/boceprevir or other peptides.

CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS

The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]- pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

CARBOXAMIDE INHIBITORS OF TGFB

Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C- 4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGFB activity.